https://scholars.lib.ntu.edu.tw/handle/123456789/637650
Title: | Study Protocol of a Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in COVID-19 Patients with Comorbidities | Authors: | WANG-DA LIU HSIN-AN HOU KO-JEN LI Qin, Albert Tsai, Chan-Yen WANG-HUEI SHENG |
Keywords: | Anti-SARS-CoV-2 drugs; Anti-SARS-CoV-2 efficacy; COVID-19; Patients with comorbidities; Randomized clinical trial; Ropeginterferon alfa-2b | Issue Date: | 2024 | Source: | Advances in therapy | Abstract: | Ropeginterferon alfa-2b represents a new-generation PEGylated interferon. It is approved for the treatment of polycythemia vera and shows promising anti-SARS-CoV-2 activities. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/637650 | ISSN: | 0741238X | DOI: | 10.1007/s12325-023-02715-7 |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.